Clinical Trial: Levetiracetam as add-on Treatment of Myoclonic Jerks in Adolescents + Adults

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Double-blind, Multicenter, Randomized, Placebo-controlled Study to Evaluate the Efficacy and Safety of Levetiracetam (LEV) (Oral Tablets of 500 mg b.i.d.) at a Dose of 3000 mg/Day as Adjunctive Trea

Brief Summary: A double-blind, placebo-controlled study to assess the efficacy of adjunctive treatment with LEV 3000mg/day in reducing myoclonic seizures in adolescents and adults suffering from idiopathic generalised epilepsy and to evaluate the safety of LEV in the same population.

Detailed Summary:
Sponsor: UCB Pharma

Current Primary Outcome: Responder rate in myoclonic (type IIB) seizures days over 16 weeks

Original Primary Outcome: Same as current

Current Secondary Outcome: Safety and tolerability of levetiracetam by means of AE, laboratory assessments, plasma concentration

Original Secondary Outcome: Same as current

Information By: UCB Pharma

Dates:
Date Received: September 6, 2005
Date Started: November 2001
Date Completion:
Last Updated: September 16, 2013
Last Verified: February 2010